You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Dosing schedule

VYXEOS (daunorubicin 44 mg/m2 and
cytarabine 100 mg/m2) liposome dose and schedule1
Administered intravenously
as a 90-minute infusion
Dose
First induction daunorubicin 44 mg/m2 and
cytarabine 100 mg/m2 liposome
Days 1, 3, and 5
Second induction
(if needed)
daunorubicin 44 mg/m2 and
cytarabine 100 mg/m2 liposome
Days 1 and 3
First consolidation daunorubicin 29 mg/m2 and
cytarabine 65 mg/m2 liposome
Days 1 and 3
Second consolidation
(if needed)
daunorubicin 29 mg/m2 and
cytarabine 65 mg/m2 liposome
Days 1 and 3
  • VYXEOS is supplied in a single-dose vial containing 44 mg of daunorubicin and 100 mg of cytarabine1
  • Calculate the number of vials of VYXEOS needed based on the daunorubicin dose

Dosing considerations

  • Prior to initiating each cycle, calculate the prior cumulative anthracycline exposure for the patient
  • Second induction can be started 2 to 5 weeks after first induction in patients not achieving a response
  • Assess cardiac function, complete blood counts, and liver and renal function before each consolidation cycle
  • Do not start consolidation until the absolute neutrophil count recovers to greater than 0.5 Gi/L and the platelet count recovers to greater than 50 Gi/L in the absence of unacceptable toxicity
  • Administer the first consolidation cycle 5 to 8 weeks after the start of last induction
  • Administer the second consolidation cycle 5 to 8 weeks after the start of the first consolidation cycle in patients who do not show disease progression or unacceptable toxicity

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.